Modeling of human P450 oxidoreductase structure by in silico mutagenesis and MD simulation

Molecular and Cellular Endocrinology

Volumn 313, Issue 1-2, 2009, Pages 17-22

  Flück, Christa E ^a   Mullis, Primus E ^a   Pandey, Amit V ^a  

^a Department of Clinical Research   (Switzerland)

Author keywords

Antely Bixler syndrome; CPR; Cytochrome P450; MD simulations; NADPH P450 oxidoreductase; POR; Sex steroids

Indexed keywords

OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE P450 OXIDOREDUCTASE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; COMPUTER MODEL; COMPUTER SIMULATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME STRUCTURE; GENE MUTATION; GENETIC POLYMORPHISM; MOLECULAR DYNAMICS; MUTAGENESIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; SPECIES COMPARISON;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; MUTAGENESIS; NADPH-FERRIHEMOPROTEIN REDUCTASE; PROTEIN CONFORMATION; RATS; REPRODUCIBILITY OF RESULTS; SEQUENCE ALIGNMENT;

EID: 70349487294     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.09.001     Document Type: Article

References (52)

1. Adachi M., Asakura Y., et al. POR R457H is a global founder mutation causing Antley-Bixler syndrome with autosomal recessive trait. Am. J. Med. Genet. A 140 6 (2006) 633-635
2. Adachi M., Tachibana K., et al. Compound heterozygous mutations of cytochrome P450 oxidoreductase gene (POR) in two patients with Antley-Bixler syndrome. Am. J. Med. Genet. 128A 4 (2004) 333-339
3. Agrawal V., Huang N., et al. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet. Genom. 18 7 (2008) 569-576
4. Arlt W., Walker E.A., et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 363 9427 (2004) 2128-2135
5. Auchus R.J., Lee T.C., et al. Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer. J. Biol. Chem. 273 6 (1998) 3158-3165
6. Bowie J.U., Luthy R., et al. A method to identify protein sequences that fold into a known three-dimensional structure. Science 253 5016 (1991) 164-170
7. Colovos C., and Yeates T.O. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci. 2 9 (1993) 1511-1519
8. Dhir V., Ivison H.E., et al. Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P. Mol. Endocrinol. 21 8 (2007) 1958-1968
9. Flück C.E., Nicolo C., et al. Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase. Fundam. Clin. Pharmacol. 21 4 (2007) 399-410
10. Flück C.E., Pandey A.V., et al. P450 oxidoreductase deficiency-a new form of congenital adrenal hyperplasia. Endocr. Dev. 13 (2008) 67-81
11. Flück C.E., Tajima T., et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat. Genet. 36 3 (2004) 228-230
12. Fukami M., Nishimura G., et al. Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients. J. Clin. Endocrinol. Metab. (2009)
13. Ghosh D., Griswold J., et al. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 457 7226 (2009) 219-223
14. Guengerich F.P. Reduction of cytochrome b5 by NADPH-cytochrome P450 reductase. Arch. Biochem. Biophys. 440 2 (2005) 204-211
15. Hamdane D., Xia C., et al. Structure and function of an NADPH-cytochrome P450 oxidoreductase in an open conformation capable of reducing cytochrome P450. J. Biol. Chem. (2009)
16. Hart S.N., Li Y., et al. Novel SNPs in cytochrome P450 oxidoreductase. Drug Metab. Pharmacokinet. 22 4 (2007) 322-326
17. Hart S.N., Wang S., et al. Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet. Genom. 18 1 (2008) 11-24
18. Holm L., and Park J. DaliLite workbench for protein structure comparison. Bioinformatics 16 6 (2000) 566-567
19. Hooft R.W., Sander C., et al. Objectively judging the quality of a protein structure from a Ramachandran plot. Comput. Appl. Biosci. 13 4 (1997) 425-430
20. Hooft R.W., Vriend G., et al. Errors in protein structures. Nature 381 6580 (1996) 272
21. Horecker B.L. Triphosphopyridine nucleotide-cytochrome-c reductase in liver. J. Biol. Chem. 183 2 (1950) 593-605
22. Huang N., Agrawal V., et al. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc. Natl. Acad. Sci. U.S.A. 105 5 (2008) 1733-1738
23. Huang N., Pandey A.V., et al. Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am. J. Hum. Genet. 76 5 (2005) 729-749
24. Hubbard P.A., Shen A.L., et al. NADPH-cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer. J. Biol. Chem. 276 31 (2001) 29163-29170
25. Janner M., Pandey A.V., et al. Clinical and biochemical description of a novel CYP21A2 gene mutation 962_963insA using a new 3D model for the P450c21 protein. Eur. J. Endocrinol. 155 1 (2006) 143-151
26. Kranendonk M., Marohnic C.C., et al. Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase. Arch. Biochem. Biophys. 475 2 (2008) 93-99
27. Krieger E., Darden T., et al. Making optimal use of empirical energy functions: force-field parameterization in crystal space. Proteins 57 4 (2004) 678-683
28. Liu H., Elstner M., et al. Quantum mechanics simulation of protein dynamics on long timescale. Proteins 44 4 (2001) 484-489
29. Lu A.Y., Junk K.W., et al. Resolution of the cytochrome P-450-containing ω-hydroxylation system of liver microsomes into three components. J. Biol. Chem. 244 13 (1969) 3714-3721
30. Luthy R., Bowie J.U., et al. Assessment of protein models with three-dimensional profiles. Nature 356 6364 (1992) 83-85
31. Matsubara T., Baron J., et al. NADPH-cytochrome P450 reductase. Arch. Biochem. Biophys. 172 2 (1976) 463-469
32. Miller W.L., Huang N., et al. P450 oxidoreductase deficiency. Lancet 364 9446 (2004) 1663
33. Nagao M., Ishibashi T., et al. Possible involvement of NADPH-cytochrome P450 reductase and cytochrome b5 on beta-ketostearoyl-CoA reduction in microsomal fatty acid chain elongation supported by NADPH. FEBS Lett. 155 1 (1983) 11-14
34. Nishino H., and Ishibashi T. Evidence for requirement of NADPH-cytochrome P450 oxidoreductase in the microsomal NADPH-sterol Delta7-reductase system. Arch. Biochem. Biophys. 374 2 (2000) 293-298
35. Ono T., and Bloch K. Solubilization and partial characterization of rat liver squalene epoxidase. J. Biol. Chem. 250 4 (1975) 1571-1579
36. Pandey A.V., Flück C.E., et al. P450 oxidoreductase deficiency: a new disorder of steroidogenesis affecting all microsomal P450 enzymes. Endocr. Res. 30 4 (2004) 881-888
37. Pandey A.V., Kempna P., et al. Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase. Mol. Endocrinol. 21 10 (2007) 2579-2595
38. Pandey A.V., Mellon S.H., et al. Protein phosphatase 2A and phosphoprotein SET regulate androgen production by P450c17. J. Biol. Chem. 278 5 (2003) 2837-2844
39. Pandey A.V., and Miller W.L. Regulation of 17,20 lyase activity by cytochrome b5 and by serine phosphorylation of P450c17. J. Biol. Chem. 280 14 (2005) 13265-13271
40. Pepe C.M., Saraco N.I., et al. The cytochrome P450 aromatase lacking exon 5 is associated with a phenotype of nonclassic aromatase deficiency and is also present in normal human steroidogenic tissues. Clin. Endocrinol. (Oxf.) 67 5 (2007) 698-705
41. Phillips A.H., and Langdon R.G. Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization, and kinetic studies. J. Biol. Chem. 237 (1962) 2652-2660
42. Ramachandran G.N., Ramakrishnan C., et al. Stereochemistry of polypeptide chain configurations. J. Mol. Biol. 7 (1963) 95-99
43. Roman L.J., McLain J., et al. Chimeric enzymes of cytochrome P450 oxidoreductase and neuronal nitric-oxide synthase reductase domain reveal structural and functional differences. J. Biol. Chem. 278 28 (2003) 25700-25707
44. Sato T., Sakaguchi M., et al. The amino-terminal structures that determine topological orientation of cytochrome P-450 in microsomal membrane. EMBO J. 9 8 (1990) 2391-2397
45. Shephard E.A., Phillips I.R., et al. Isolation of a human cytochrome P-450 reductase cDNA clone and localization of the corresponding gene to chromosome 7q11.2. Ann. Hum. Genet. 53 Pt 4 (1989) 291-301
46. Sim S.C., Miller W.L., et al. Nomenclature for alleles of the cytochrome P450 oxidoreductase gene. Pharmacogenet. Genom. 19 7 (2009) 565-566
47. Vriend G. WHAT IF: a molecular modeling and drug design program. J. Mol. Graph. 8 1 (1990) 52-56 29
48. Wang M., Roberts D.L., et al. Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. Proc. Natl. Acad. Sci. U.S.A. 94 16 (1997) 8411-8416
49. Williams Jr. C.H., and Kamin H. Microsomal triphosphopyridine nucleotide-cytochrome c reductase of liver. J. Biol. Chem. 237 (1962) 587-595
50. Worth C.L., Bickerton G.R., et al. A structural bioinformatics approach to the analysis of nonsynonymous single nucleotide polymorphisms (nsSNPs) and their relation to disease. J. Bioinform. Comput. Biol. 5 6 (2007) 1297-1318
51. Yamano S., Aoyama T., et al. Human NADPH-P450 oxidoreductase: complementary DNA cloning, sequence and vaccinia virus-mediated expression and localization of the CYPOR gene to chromosome 7. Mol. Pharmacol. 36 1 (1989) 83-88
52. Zhang L.H., Rodriguez H., et al. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc. Natl. Acad. Sci. U.S.A. 92 23 (1995) 10619-10623